Angiotensin receptor blockers (ARBs)
A class of medicines that block the receptor that angiotensin II acts on. MeSH notes that some of them are used as blood pressure lowering agents. The US label read for one ARB lists high blood pressure in adults and children, lowering the risk of stroke in people who have high blood pressure and left ventricular hypertrophy (the label says there is evidence that this benefit does not apply to Black patients), and a kidney disease of type 2 diabetes in people with a history of high blood pressure. It also carries a boxed warning that these drugs can cause injury and death to the developing fetus.
Also called ARBs · ARB · Angiotensin II receptor blockers · Angiotensin receptor blockers · Angiotensin receptor blocker
- Drug
- In this atlas
Overview
Technical summary
Class page. MeSH descriptor D047228 (Angiotensin II Type 1 Receptor Blockers, last updated 2020-05-27) is an exact match, and its scope note gives the class description. The label read is the US prescribing label of one brand-name losartan potassium tablet (application NDA020386, effective 2026-01-20 in openFDA). It calls the medicine an angiotensin II receptor blocker. Its first list of uses says children greater than 6 years old, while the detailed hypertension text says pediatric patients 6 years of age and older; both are kept side by side. The label says the stroke benefit has evidence that it does not apply to Black patients. A separate claim records the boxed warning on fetal toxicity; the recipient of that risk is the fetus. One label stands for one product, so other members of the class may list other uses, and no other label was read. This page gives no dose, no trial result and no guideline statement. Medicines of the class that have their own pages are filed under it.
Trials at a glance
The figures count the 14 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 14
- Phase 3 or 4
- 11
- Recruiting
- 3
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Unknown status | All statuses |
|---|---|---|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 3 |
| Phase 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Phase 4 | 2 | 1 | 0 | 1 | 1 | 1 | 3 | 9 |
| All phases | 3 | 1 | 1 | 3 | 1 | 1 | 4 | 14 |
Conditions these trials study
- Hypertension (high blood pressure)
- Cardiomyopathy (heart muscle disease)
- Aortic stenosis
- Heart valve disease
- Hypertrophic cardiomyopathy
- Adult congenital heart disease
- Chronic kidney disease (CKD)
- Congenital heart disease
- Dilated cardiomyopathy
- Heart attack (myocardial infarction)
Sponsors with the most trials
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Carelon Research
- Chong Kun Dang Pharmaceutical
- Cristina Avendaño Solá
- Henning Bundgaard
Drugs in this class
5 drugs in this atlas are filed under Angiotensin receptor blockers (ARBs), with the registry trials and FDA regulatory decisions this atlas holds for each. With Angiotensin receptor blockers (ARBs) itself, the class has 79 distinct trials and 46 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- MeSH says these agents antagonize the angiotensin II type 1 receptor. A US label says the medicine and its active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
Claims and evidence
Context People with hypertension (adults and pediatric patients 6 years and older), hypertension with left ventricular hypertrophy, or diabetic nephropathy in type 2 diabetes, as described in the US label of an ARB
- Recipient
- Mixed recipients
- Population
- Patients described in the indications section of the label: adults and pediatric patients 6 years of age and older with hypertension, patients with hypertension and left ventricular hypertrophy, and patients with type 2 diabetes, a history of hypertension, an elevated serum creatinine and proteinuria.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (US drug label)
- Life stage
- Adults, and for hypertension also pediatric patients 6 years of age and older, as the label states
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Adults and pediatric patients 6 years of age and older with hypertension
- Hypertension with left ventricular hypertrophy
- Type 2 diabetes with a history of hypertension, elevated serum creatinine and proteinuria (diabetic nephropathy)
- Excluded
- None stated
The US label of COZAAR (losartan potassium tablets, Organon LLC, application NDA020386; the version dated 2026-01-20 in openFDA) calls the medicine an angiotensin II receptor blocker (ARB). It lists treating hypertension in adults and pediatric patients 6 years of age and older, reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. The label says there is evidence that the stroke benefit does not apply to Black patients. MeSH says the class antagonizes the angiotensin II type 1 receptor and that some of its members are used as antihypertensive agents.
Applies to Mixed recipients People with hypertension (adults and pediatric patients 6 years and older), hypertension with left ventricular hypertrophy, or diabetic nephropathy in type 2 diabetes, as described in the US label of an ARB
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's first list says children greater than 6 years old, while its detailed hypertension text says pediatric patients 6 years of age and older; the two were not reconciled. Other ARB labels list different uses. The label's contraindications, other warnings, interactions and dosing were not recorded; its boxed warning is recorded in a separate claim. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that call the medicine an ARB and list its uses.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260120.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports MeSH scope note for descriptor D047228 (Angiotensin II Type 1 Receptor Blockers)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note: the class antagonizes the angiotensin II type 1 receptor; some are antihypertensive agents.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
854b15d2482adbea17ec622f381141506c3f5275a47ddce16330c4c2365c6e66- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-11-09 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
Context The developing fetus, for a person taking an ARB during pregnancy, as described in a US label boxed warning
- Recipient
- Fetal
- Population
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (US drug label)
- Life stage
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Pregnancy during which the medicine is taken (risk to the fetus)
- Excluded
- None stated
The same US label of COZAAR carries a boxed warning titled fetal toxicity. It says that drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Applies to Fetal The developing fetus, for a person taking an ARB during pregnancy, as described in a US label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do when pregnancy is detected; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].boxed_warning[0]
- How it applies
- The boxed warning title and its fetal-injury statement.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260120.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In pregnancy 1
The same US label of COZAAR carries a boxed warning titled fetal toxicity. It says that drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Applies to Fetal The developing fetus, for a person taking an ARB during pregnancy, as described in a US label boxed warning
Population, setting and follow-up
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Prescription medicine, as described in the US label
- United States (US drug label)
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do when pregnancy is detected; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].boxed_warning[0]
- How it applies
- The boxed warning title and its fetal-injury statement.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260120.
- Retrieved
- Source effective date
- 2026-01-20
- Source state
- Current
- Version fingerprint
536990a875d291986fb51dbf7b10cf8ee959b18f260426b2261c43216a2378f9- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact A US label lists treating high blood pressure as an indication: Hypertension (high blood pressure)
Applies to Mixed recipients People with hypertension (adults and pediatric patients 6 years and older), hypertension with left ventricular hypertrophy, or diabetic nephropathy in type 2 diabetes, as described in the US label of an ARB
The US label of COZAAR (losartan potassium tablets, Organon LLC, application NDA020386; the version dated 2026-01-20 in openFDA) calls the medicine an angiotensin II receptor blocker (ARB). It lists treating hypertension in adults and pediatric patients 6 years of age and older, reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. The label says there is evidence that the stroke benefit does not apply to Black patients. MeSH says the class antagonizes the angiotensin II type 1 receptor and that some of its members are used as antihypertensive agents.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's first list says children greater than 6 years old, while its detailed hypertension text says pediatric patients 6 years of age and older; the two were not reconciled. Other ARB labels list different uses. The label's contraindications, other warnings, interactions and dosing were not recorded; its boxed warning is recorded in a separate claim. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact A US label lists diabetic kidney disease in type 2 diabetes as an indication: Diabetic kidney disease
Applies to Mixed recipients People with hypertension (adults and pediatric patients 6 years and older), hypertension with left ventricular hypertrophy, or diabetic nephropathy in type 2 diabetes, as described in the US label of an ARB
The US label of COZAAR (losartan potassium tablets, Organon LLC, application NDA020386; the version dated 2026-01-20 in openFDA) calls the medicine an angiotensin II receptor blocker (ARB). It lists treating hypertension in adults and pediatric patients 6 years of age and older, reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and treating diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. The label says there is evidence that the stroke benefit does not apply to Black patients. MeSH says the class antagonizes the angiotensin II type 1 receptor and that some of its members are used as antihypertensive agents.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's first list says children greater than 6 years old, while its detailed hypertension text says pediatric patients 6 years of age and older; the two were not reconciled. Other ARB labels list different uses. The label's contraindications, other warnings, interactions and dosing were not recorded; its boxed warning is recorded in a separate claim. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 14
Record details
- Record id
cardio:angiotensin-receptor-blockers-arbs- Content hash
535c4a0337f49694655bf3902ccd148b35a5ba74b840c493a28c7c297c25318d